KLACID MR TABLET 500 mg Singapore - English - HSA (Health Sciences Authority)

klacid mr tablet 500 mg

abbott laboratories (singapore ) private limited - clarithromycin - tablet, extended release - 500 mg - clarithromycin 500 mg

TERRAMYCIN OPHTHALMIC OINTMENT Singapore - English - HSA (Health Sciences Authority)

terramycin ophthalmic ointment

pfizer private limited - oxytetracycline hcl eqv oxytetracycline; polymyxin b sulphate eqv polymyxin b - ointment - 5 mg/g - oxytetracycline hcl eqv oxytetracycline 5 mg/g; polymyxin b sulphate eqv polymyxin b 10000 iu/g

KLACID FORTE TABLET 500 mg Singapore - English - HSA (Health Sciences Authority)

klacid forte tablet 500 mg

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 500 mg - clarithromycin 500 mg

KLACID IV FOR INJECTION 500 mgvial Singapore - English - HSA (Health Sciences Authority)

klacid iv for injection 500 mgvial

abbott laboratories (singapore ) private limited - clarithromycin - injection, powder, for solution - 500 mg/vial - clarithromycin 500 mg/vial

KLACID TABLET 250 mg Singapore - English - HSA (Health Sciences Authority)

klacid tablet 250 mg

abbott laboratories (singapore ) private limited - clarithromycin - tablet, film coated - 250 mg - clarithromycin 250 mg

ATGAM INJECTION 50 mgml Singapore - English - HSA (Health Sciences Authority)

atgam injection 50 mgml

pfizer private limited - horse gamma globulin - injection - 50 mg/ml - horse gamma globulin 50 mg/ml

ISOPTIN SR TABLET 240 mg Singapore - English - HSA (Health Sciences Authority)

isoptin sr tablet 240 mg

abbott laboratories (singapore ) private limited - verapamil hydrochloride - tablet, film coated - 240 mg - verapamil hydrochloride 240.0 mg

Lataneau Plus 50 microgram/ml + 5mg/ml Eye Drops, Solution Malta - English - Medicines Authority

lataneau plus 50 microgram/ml + 5mg/ml eye drops, solution

alapis s.a. 2 aftokratoros nikolaou street, 17671 athens, greece - timolol, latanoprost - eye drops, solution - timolol 5 mg/ml latanoprost 50 µg/ml - ophthalmologicals

Skin semi-occlusive dressing Australia - English - Department of Health (Therapeutic Goods Administration)

skin semi-occlusive dressing

stratpharma pty ltd - 62069 - skin semi-occlusive dressing - stratacel is a semi-occlusive wound dressing intended to cover a wound, to provide and support a moist wound environment, and to allow the exchange of gases such as oxygen and water vapor through the device. because stratacel is a gel, it is easily applied to large exposed surface areas and contoured skin, like the face, neck and chest. stratacel can be used with or without a secondary protective dressing. stratacel creates a moist wound environment. stratacel was developed for use as a wound dressing for the repair of damaged or compromised skin following resurfacing procedures such as: ? laser therapy (ablative and non-ablative), including tattoo removal ? dermal abrasion ? chemical peels stratacel may also be used in conjunction with other adjunctive treatments to improve overall results. stratacel contains no alcohols, parabens or fragrances and is transparent and odorless. stratacel is suitable for people with sensitive skin. stratacel may be used during pregnancy and while breastfeeding

ULTRAVIST- iopromide injection United States - English - NLM (National Library of Medicine)

ultravist- iopromide injection

bayer healthcare pharmaceuticals inc. - iopromide (unii: 712bac33mz) (iopromide - unii:712bac33mz) - iodine 240 mg in 1 ml - ultravist® injection is an iodinated contrast agent indicated for: *for information on the concentrations and doses for the pediatric population [see dosage and administration (2.3) and use in specific populations (8.4)]. risk summary there are no data on ultravist injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. iopromide crosses the placenta and reaches fetal tissues in small amounts (see data). in animal reproduction studies, intravenous administration of iopromide to pregnant rats and rabbits during organogenesis at doses up to 0.35 and 0.7 times, respectively, the maximum recommended human dose based on body surface area resulted in no relevant adverse developmental effects (see data). . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defects, loss, or other adverse outcomes. in the u.s. general p